BCM
NEO icon

Bayesian Capital Management’s NeoGenomics NEO Stock Holding History

Bayesian Capital Management’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,000
Closed -$123K – 762
2025
Q1 		$123K Buy
+13,000
New +$162K 0.02% 532
2023
Q2 		– Sell
-27,143
Closed -$473K – 974
2023
Q1 		$473K Buy
27,143
+4,000
+17% +$57K 0.06% 409
2022
Q4 		$214K Buy
23,143
+9,200
+66% +$85.8K 0.03% 577
2022
Q3 		$120K Buy
+13,943
New +$138K 0.02% 574

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bayesian Capital Management's NEO Position: Q2 2025 in Review

Bayesian Capital Management sold out of NeoGenomics (NEO) in Q2 2025, closing a stake of 13,000 shares — an estimated $123K sold.

Bayesian Capital Management first reported a position in NEO in Q3 2022 and held it in 4 quarters. The position peaked at $473K in Q1 2023. 274 funds tracked by Wall St. Rank hold NEO as of Q2 2025.

  • Bayesian Capital Management reported no remaining NeoGenomics position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 13,000 NeoGenomics shares in Q2 2025, an estimated $123K.
  • Bayesian Capital Management first reported a position in NeoGenomics in Q3 2022 and held it in 4 quarters.
  • Bayesian Capital Management's NeoGenomics position peaked at $473K in Q1 2023.
  • 274 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.